Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimics
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Driver mutations in the two histone 3.3 (H3.3) genes, H3F3A and H3F3B, were recently identified by whole genome sequencing in 95% of chondroblastoma (CB) and by targeted gene sequencing in 92% of giant cell tumour of bone (GCT). Given the high prevalence of these driver mutations, it may be possible to utilise these alterations as diagnostic adjuncts in clinical practice. Here, we explored the spectrum of H3.3 mutations in a wide range and large number of bone tumours (n = 412) to determine if these alterations could be used to distinguish GCT from other osteoclast‐rich tumours such as aneurysmal bone cyst, nonossifying fibroma, giant cell granuloma, and osteoclast‐rich malignant bone tumours and others. In addition, we explored the driver landscape of GCT through whole genome, exome and targeted sequencing (14 gene panel). We found that H3.3 mutations, namely mutations of glycine 34 in H3F3A, occur in 96% of GCT. We did not find additional driver mutations in GCT, including mutations in IDH1, IDH2, USP6, TP53. The genomes of GCT exhibited few somatic mutations, akin to the picture seen in CB. Overall our observations suggest that the presence of H3F3A p.Gly34 mutations does not entirely exclude malignancy in osteoclast‐rich tumours. However, H3F3A p.Gly34 mutations appear to be an almost essential feature of GCT that will aid pathological evaluation of bone tumours, especially when confronted with small needle core biopsies. In the absence of H3F3A p.Gly34 mutations, a diagnosis of GCT should be made with caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“Reads were visualised using integrative genomics viewer (IGV) [14] with the appropriate browser extensible data (BED) files for all 14 genes.”
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · cited 1×
“G34M in aggressive brain tumours, in which TP53 mutations are also seen [17], the 3 GCT with these alterations followed a typical clinical course and did not harbour TP53 mutations, with 2/3 having at least 5 years follow-up (p.”
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345 · cited 2×
“This proposition is supported by in vitro experimental evidence using glioma cell lines showing a clear link between histone mutation, methylation, gene expression and tumourigenesis [18,19].”
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023 · cited 2×
“3 alterations along with other common bone cancer genes including IDH1/2 alterations in cartilaginous tumours [8,9], GRM1 rearrangements of chondromyxoid fibromas [26] and USP6 alterations in ABC [5,6,22] adds to the armoury with which pathologists can provide accurate diagnoses.”
Self-citationDistinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
Behjati, S., Tarpey, P. S., Presneau, N., Scheipl, S., Pillay, N., Van Loo, P., Wedge, D. C., Cooke, S. L., Gundem, G., Davies, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2814 · Cited by 854
Self-citationTargeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804 · cited 8×
“No mutations, specifically no TP53, IDH1 and IDH2 alterations, were identified (Supporting Information Table 2).”
InfluentialThe histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
Chan, K.-M., Fang, D., Gan, H., Hashizume, R., Yu, C., Schroeder, M., Gupta, N., Mueller, S., James, C. D., Jenkins, R., et al. (2013) · Genes & Development · doi:10.1101/gad.217778.113 · Cited by 707
Cited by
Wright, J. M., & Vered, M. (2017) · Head and Neck Pathology · doi:10.1007/s12105-017-0794-1 · Cited by 681
The 2020 WHO Classification of Tumors of Bone: An Updated Review
Choi, J. H., & Ro, J. Y. (2021) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000293 · Cited by 395
Gutteridge, A., Rathbone, V. M., Gibbons, R., Bi, M., Archard, N., Davies, K. E. J., Brown, J., Plagnol, V., Pillay, N., Amary, F., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1146 · Cited by 38
Self-citation
Metadata
- Authors
- Presneau, N., Baumhoer, D., Behjati, S., Pillay, N., Tarpey, P., Campbell, P. J., Jundt, G., Hamoudi, R., Wedge, D. C., Loo, P. V., Hassan, A. B., Khatri, B., Ye, H., Tirabosco, R., Amary, M. F., & Flanagan, A. M.
- Venue
- The Journal of Pathology: Clinical Research
- Publisher
- Wiley
- Published
- 2015-03-16
- Volume
- 1
- Issue
- 2
- Pages
- 113-123
- ISSN
- 2056-4538 (ISSN-L)
- OpenAlex
- W1819350126
- Cited by
- 163
- References
- 8
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimics. https://app.cochat.ai/papers/10.1002/cjp2.13
- The paper
- Presneau, N., Baumhoer, D., Behjati, S., Pillay, N., Tarpey, P., Campbell, P. J., Jundt, G., Hamoudi, R., Wedge, D. C., Loo, P. V., Hassan, A. B., Khatri, B., Ye, H., Tirabosco, R., Amary, M. F., & Flanagan, A. M. (2015). Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimics. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/cjp2.13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.